Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens.

Špunarová,  Michaela; Malčíková,  Jitka; Tom,  Nikola; Borský,  Marek; Brychtová,  Yvona; Doubek,  Michael; Panovská,  Anna; Divíšková,  Eva; Mráz,  Marek; Pospíšilová,  Šárka; Mayer,  Jiří; Trbušek,  Martin

Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens.

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	ŠPUNAROVÁ Michaela MALČÍKOVÁ Jitka TOM Nikola BORSKÝ Marek BRYCHTOVÁ Yvona DOUBEK Michael PANOVSKÁ Anna DIVÍŠKOVÁ Eva MRÁZ Marek POSPÍŠILOVÁ Šárka MAYER Jiří TRBUŠEK Martin
Year of publication	2017
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens. Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens.
Related projects:	Predictive stratification of CLL patients for therapy involving monoclonal antibodies targeting CD20 Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV